JP2010512774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512774A5 JP2010512774A5 JP2009542133A JP2009542133A JP2010512774A5 JP 2010512774 A5 JP2010512774 A5 JP 2010512774A5 JP 2009542133 A JP2009542133 A JP 2009542133A JP 2009542133 A JP2009542133 A JP 2009542133A JP 2010512774 A5 JP2010512774 A5 JP 2010512774A5
- Authority
- JP
- Japan
- Prior art keywords
- bacteriophage
- protein
- recombinant
- gene
- bank
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001515965 unidentified phage Species 0.000 claims description 226
- 108090000623 proteins and genes Proteins 0.000 claims description 177
- 102000004169 proteins and genes Human genes 0.000 claims description 97
- 241000894006 Bacteria Species 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 78
- 108091034117 Oligonucleotide Proteins 0.000 claims description 38
- 230000008685 targeting Effects 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 34
- 101710086578 Chaperone protein gp12 Proteins 0.000 claims description 30
- 101710102575 Pre-neck appendage protein Proteins 0.000 claims description 30
- 230000006801 homologous recombination Effects 0.000 claims description 25
- 238000002744 homologous recombination Methods 0.000 claims description 25
- 230000010076 replication Effects 0.000 claims description 23
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 238000003780 insertion Methods 0.000 claims description 14
- 101800000385 Transmembrane protein Proteins 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 101150064129 slp gene Proteins 0.000 claims description 7
- 101800001670 GP38 Proteins 0.000 claims description 6
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 6
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241001624918 unidentified bacterium Species 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 101100351324 Homo sapiens PDPN gene Proteins 0.000 claims description 4
- 102100037265 Podoplanin Human genes 0.000 claims description 4
- 210000000234 capsid Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 230000003321 amplification Effects 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 241000701533 Escherichia virus T4 Species 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 12
- 239000007795 chemical reaction product Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 230000007923 virulence factor Effects 0.000 description 8
- 239000000304 virulence factor Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000005273 aeration Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 230000010065 bacterial adhesion Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000001320 lysogenic effect Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101150063735 DNASE1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000724228 Enterobacteria phage RB69 Species 0.000 description 1
- 101001052019 Enterobacteria phage T4 Short tail fiber protein gp12 Proteins 0.000 description 1
- 241000701536 Enterobacteria phage T6 Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001333951 Escherichia coli O157 Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000701988 Escherichia virus T5 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700028353 OmpC Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 101710166729 Tail fiber protein Proteins 0.000 description 1
- 101000717237 Tobacco streak virus (strain WC) RNA-directed RNA polymerase 2a Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0655721A FR2910492B1 (fr) | 2006-12-20 | 2006-12-20 | Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages |
| PCT/FR2007/002101 WO2008093009A2 (fr) | 2006-12-20 | 2007-12-18 | Procédé de préparation de bactériophages modifiés par insertion de séquences aléatoires dans les protéines de ciblage desdits bactériophages |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512774A JP2010512774A (ja) | 2010-04-30 |
| JP2010512774A5 true JP2010512774A5 (https=) | 2013-08-29 |
Family
ID=38293109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542133A Pending JP2010512774A (ja) | 2006-12-20 | 2007-12-18 | バクテリオファージのスクリーニング蛋白質へのランダム配列挿入により改変されたバクテリオファージの作製方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9315803B2 (https=) |
| EP (2) | EP2653536A1 (https=) |
| JP (1) | JP2010512774A (https=) |
| AU (1) | AU2007346006B2 (https=) |
| CA (1) | CA2673579C (https=) |
| FR (1) | FR2910492B1 (https=) |
| WO (1) | WO2008093009A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2945049B1 (fr) | 2009-04-30 | 2013-10-04 | Pherecydes Pharma | Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote |
| WO2017174809A1 (en) * | 2016-04-08 | 2017-10-12 | Phico Therapeutics Ltd | Modifying bacteriophage |
| CN112823206B (zh) * | 2018-10-17 | 2024-04-16 | 深圳华大生命科学研究院 | 从细菌全基因组序列中挖掘温和型噬菌体的方法、装置和存储介质 |
| US11724057B2 (en) | 2019-12-16 | 2023-08-15 | Melissa H. Egts | Protective, sanitary, securable nasal cannula cover |
| USD942002S1 (en) | 2019-12-16 | 2022-01-25 | Melissa H. Egts | Nasal cannula cover |
| DE102024113842A1 (de) * | 2024-05-16 | 2025-11-20 | bifa Umweltinstitut GmbH | Verfahren zur Verringerung der bakteriellen Last auf bzw. in einer Klimaanlage |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270939B (it) * | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
| US6203986B1 (en) * | 1998-10-22 | 2001-03-20 | Robert H. Singer | Visualization of RNA in living cells |
| CA2430501A1 (en) | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Method for produce sanitation using bacteriophages |
| ES2252263T3 (es) * | 2000-07-25 | 2006-05-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Bacteriofago que tiene una gama de hospedadores multiple. |
| GB0028130D0 (en) * | 2000-11-17 | 2001-01-03 | Phico Therapeutics Ltd | Polypeptide and uses thereof |
| WO2006066224A2 (en) * | 2004-12-14 | 2006-06-22 | Yale University | Virulence targeted antibiotics |
-
2006
- 2006-12-20 FR FR0655721A patent/FR2910492B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-18 WO PCT/FR2007/002101 patent/WO2008093009A2/fr not_active Ceased
- 2007-12-18 CA CA2673579A patent/CA2673579C/fr active Active
- 2007-12-18 US US12/520,789 patent/US9315803B2/en not_active Expired - Fee Related
- 2007-12-18 EP EP12192306.4A patent/EP2653536A1/fr not_active Withdrawn
- 2007-12-18 JP JP2009542133A patent/JP2010512774A/ja active Pending
- 2007-12-18 AU AU2007346006A patent/AU2007346006B2/en not_active Ceased
- 2007-12-18 EP EP07872388A patent/EP2097516B1/fr not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schneider | Bacteriophage-mediated horizontal gene transfer: transduction | |
| US10626394B2 (en) | Synthetic bacteriophages and bacteriophage compositions | |
| CN108135949A (zh) | 递送媒介物 | |
| Chamakura et al. | Single-gene lysis in the metagenomic era | |
| JP2010512774A5 (https=) | ||
| US9315803B2 (en) | Method for the preparation of modified bacteriophages by insertion of random sequences in the targeting proteins of said bacteriophages | |
| US9029134B2 (en) | Linear vectors, host cells and cloning methods | |
| JP7323178B2 (ja) | Ｌ型細菌における合成バクテリオファージゲノムの再起動 | |
| Ceyssens et al. | Isolation and Characterization of lytic bacteriophages infecting Pseudomonas aerugionsa | |
| Salmi et al. | Genetic determinants of immunity and integration of temperate Myxococcus xanthus phage Mx8 | |
| JP5622394B2 (ja) | 遺伝子配列を前記遺伝子配列の所定の内部セグメントの一致度を維持しながらランダムに多様化する方法 | |
| Aljarbou et al. | Genotyping, morphology and molecular characteristics of a lytic phage of Neisseria strain obtained from infected human dental plaque | |
| Martínez et al. | Bacteriophages of lactic acid bacteria and biotechnological tools | |
| JP5773987B2 (ja) | 溶菌性バクテリオファージをこの宿主細菌中に固定化することにより該バクテリオファージのゲノムを修飾する方法 | |
| Halmillawewa | Isolation, characterization, and applications of rhizobiophages | |
| Parcey | The Role of CRISPR-Mediated Phage Resistance in the Development of Phage-Based Biocontrol for Erwinia amylovora | |
| Knezevic et al. | Phages from genus Bruynoghevirus and phage therapy: Pseudomonas phage delta case. Viruses 2021; 13: 1965 | |
| WO2025008620A1 (en) | Bacteriophage compositions | |
| Ravin | ReplicationLinear Phage-Plasmid and MaintenanceN15 of | |
| Lucchini | Genetic diversity of Streptococcus thermophilus phages and development of phage-resistant starters for the dairy industry | |
| Seaton | Defining the Requirements for Early Gene Expression in Bacteriophage HK639 | |
| Magrini | Characterizing the mechanism of site-specific recombination of temperate bacteriophage Mx8 of Myxococcus xanthus | |
| Whittle | Isolation and characterisation of four novel bacteriophages infecting clinically relevant PCR ribotypes of Clostridium difficile | |
| Hisham | Characterization of a New Bacterial Virus from Orangutan (Pongo Pygmaeus) |